Fox Run Management, L.L.C. Axsome Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$69.25 - $82.21 $363,562 - $431,602	5,250 New	5,250 $366,000
Q4 2022 Feb 07, 2023	SELL	$39.94 - $79.72 $97,892 - $195,393	-2,451 Reduced 41.78%	3,416 $263,000
Q3 2022 Nov 07, 2022	BUY	$36.06 - $69.85 $211,564 - $409,809	5,867 New	5,867 $262,000
Q2 2021 Aug 05, 2021	SELL	$50.63 - $73.5 $192,242 - $279,079	-3,797 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$55.91 - $81.44 $212,290 - $309,227	3,797 New	3,797 $215,000

288

40.4M

365K

428K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.84B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.